Normal spontaneous labor at term without maternal or fetal complications does not always occur. In these situations, pharmacological intervention is often the safest and most suitable method of delivery. The pharmacological management of labor includes the use of multiple agents that alter cervical dilatation and uterine contractions, resulting in delivery of the fetus and treatment of postpartum emergencies. This article provides a description of normal and abnormal labor patterns and possible peripartum complications. The use of oxytocin, ergot derivatives, and prostaglandins for augmentation of dysfunctional labor, induction of labor, and management of peripartum emergencies is discussed to provide information on availability of product, indications for use, clinical efficacy, potential adverse effects, and contraindications to use.
Get full access to this article
View all access options for this article.
References
1.
FriedmanEA: Normal and dysfunctional labor, in CohenWRAckerDBFriedmanEA (eds): Management of Labor. Rockville, MD, Aspen Publishers, 1989, pp 1–18.
2.
FriedmanEA: Assessment of labor progression, in FriedmanEAAckerDBSachsBP (eds): Obstetrical Decision Making. Philadelphia, PA, B.C. Decker, 1987, pp 234–235.
American College of Obstetricians and Gynecologists: Induction and augmentation of labor. ACOG Technical Bulletin 157. Washington, DC: American College of Obstetricians and Gynecologists, 1991.
BishopEH: Pelvic scoring for elective induction. Obstet Gynecol24:266–268, 1964.
18.
SatinAJHankinsGDVYeomansER: A prospective study of two dosing regimens of oxytocin for the induction of labor in patients with unfavorable cervices. Am J Obstet Gynecol165:980–984, 1991.
19.
HauthJCHankinsGDVGilstrapLC: Uterine contraction pressures with oxytocin induction/augmentation. Obstet Gynecol68:305–309, 1986.
CohenWR: The third stage and postpartum hemorrhage, in CohenWRAckerDBFriedmanEA (eds): Management of Labor. Rockville, MD, Aspen Publishers, 1989, pp 61–76.
PeyserMRKupfermincMJ: Management of severe postpartum hemorrhage by intrauterine irrigation with prostaglandin E2. Am J Obstet Gynecol162:694–696, 1990.
24.
HayashiRHCastilloMSNoahML: Management of severe postpartum hemorrhage with a prostaglandin F2 alpha analogue. Obstet Gynecol63:806–808, 1984.
25.
ToppozadaMEl-BossatyMEl-RahmanHA: Control of intractable atonic postpartum hemorrhage by 15-methylprostaglandin F2 alpha. Obstet Gynecol58:327–330, 1981.
26.
LichterED: Late postpartum hemorrhage, in FriedmanEAAckerDBSachsBP (eds): Obstetrical Decision Making. Philadelphia, PA, B.C. Decker, 1987, pp 274–275.
27.
AndrinopoulosGCMendenhallHW: Prostaglandin F2 alpha in the management of delayed postpartum hemorrhage. Am J Obstet Gynecol145:217–218, 1983.
GolanALidorALWexlerS: A new method for the management of the retained placenta. Am J Obstet Gynecol146:708–709, 1983.
30.
KristiansenFVFrostLKaspersenP: The effect of oxytocin injection into the umbilical vein for the management of the retained placenta. Am J Obstet Gynecol156:979–980, 1987.
31.
HackerNFBiggsJSG: Blood pressure changes when uterine stimulants are used after normal delivery. Br J Obstet Gynaecol86:633–636, 1979.
JohnsonAB: A new concept in the replacement of the inverted uterus and a report of nine cases. Am J Obstet Gynecol57:557–562, 1949.
34.
ThieryMDelbekeL: Acute puerperal uterine inversion: Two-step management with a beta-mimetic and a prostaglandin. Am J Obstet Gynecol153:891–892, 1985.
35.
KovacsBWDeVoreGR: Management of acute and subacute puerperal uterine inversion with terbutaline sulfate. Am J Obstet Gynecol150:784–786, 1984.
36.
CatanzariteVAMoffittKDBakerML: New approaches to the management of acute puerperal uterine inversion. Obstet Gynecol68:7S–10S, 1986.
37.
HeylPSStubblefieldPGPhillippeM: Recurrent inversion of the puerperal uterus managed with 15(S)-15-methylprostaglandin F2 alpha and uterine packing. Obstet Gynecol63:263–264, 1984.
38.
RailTWSchleiferLS: Oxytocin, prostaglandins, ergot alkaloids, and other drugs; Tocolytic agents, in GilmanAGGoodmanLSRailTW (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY, Macmillan, 1985, pp 926–945.
39.
Calderyo-BarciaRPoseiroJJ: Physiology of the uterine contraction. Clin Obstet Gynecol3:386–408, 1960.
40.
SatinAJLevenoKJShermanML: Factors affecting the dose response to oxytocin for labor stimulation. Am J Obstet Gynecol166:1260–1261, 1992.
41.
McEvoyGKLitvakKWelshOH (eds): AHFS Drug Information '92. Bethesda, MA, American Society of Hospital Pharmacists, 1992.
42.
SeitchikJAmicoJRobinsonAG: Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics. Am J Obstet Gynecol150:225–228, 1984.
43.
SeitchikJCastilloM: Oxytocin augmentation of dysfunctional labor. II. Uterine activity data. Am J Obstet Gynecol145:526–529, 1983.
44.
CahillDJBoylanPCO'HerlihyC: Does oxytocin augmentation increase perinatal risk in primigravid labor?. Am J Obstet Gynecol166:847–850, 1992.
45.
SatinAJLevenoKJShermanML: High-versus low-dose oxytocin for labor stimulation. Obstet Gynecol80:111–116, 1992.
46.
SokolRJBrindleyBA: Practical diagnosis and management of abnormal labor, in ScottJRDiSaiaPJHammondCB (eds): Danforth's Obstetrics and Gynecology. Philadelphia, PA, Lippincott, 1990, pp 585–637.
47.
CibilsLAHendricksCH: Effect of ergot derivatives and sparteine sulfate upon the human uterus. J Reprod Med2:147–167, 1969.
48.
RayburnWFWapnerRJBarssVA: An intravaginal controlled-release prostaglandin E2 pessary for cervical ripening and initiation of labor at term. Obstet Gynecol79:374–379, 1992.
49.
CrawfordSYDombrowskiSR: Extemporaneous compounding activities and the associated informational needs of pharmacists. Am J Hosp Pharm48:1205–1210, 1991.
50.
PerrymanDYeastJDHoistV: Cervical ripening: A randomized study comparing prostaglandin E2 gel to prostaglandin E2 suppositories. Obstet Gynecol79:670–672, 1992.
51.
OwenJWinklerCLHarrisB: A randomized, double blind trial of prostaglandin E2 gel for cervical ripening and meta-analysis. Am J Obstet Gynecol165:991–996, 1991.
52.
MillerAMRayburnWFSmithCV: Patterns of uterine activity after intravaginal prostaglandin E2 during preinduction cervical ripening. Am J Obstet Gynecol165: 1006–1009, 1991.
53.
MackenzieIZEmbreyMP: The influence of preinduction vaginal prostaglandin E2 gel upon subsequent labour. Br J Obstet Gynaecol85:657–661, 1978.
54.
WitterFRRoccoLEJohnsonTRB: A randomized trial of prostaglandin E2 in a controlled-release vaginal pessary for cervical ripening at term. Am J Obstet Gynecol166:830–834, 1992.
55.
EkmanGFormanAMarsalK: Intravaginal versus intracervical application of prostaglandin E2 in viscous gel for cervical priming and induction of labor at term in patients with an unfavorable cervical state. Am J Obstet Gynecol147:657–661, 1983.
56.
CohenWR: Postpartum uterine hemorrhage, in CherrySHMerkatzIR (eds): Complications of Pregnancy: Medical, Surgical, Gynecologic, Psychosocial, and Perinatal. Baltimore, MD, Williams and Wilkins, 1991, pp 1132–1141.
57.
Hemabate® Product Information: The Upjohn Company, 1991.
58.
BruceSLPaulRHVan DorstenJP: Control of postpartum uterine atony by intramyometrial prostaglandin. Obstet Gynecol59:47S–50S, 1982.
59.
CohenSMitchellJLMarxGF: Severe systemic reactions following administration of different ureotonic drugs. NY State J Med July, Aug, Sept 1060–1061, 1983.
